$104.910
+0.997 (+0.95%)收盘时
EXAS 资讯
EXAS 事件
Abbott Completes Acquisition of Exact Sciences
Abbott (ABT) announced it has completed the acquisition of Exact Sciences (EXAS), establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. Pursuant to the terms of the merger agreement, upon completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, March 20, 2026, was the last day of trading of Exact Sciences shares on the Nasdaq Stock Market.
Abbott Expects to Close Acquisition of Exact Sciences on March 23
Abbott (ABT) expects to close the acquisition of Exact Sciences (EXAS) on Monday, March 23. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages. As previously communicated, this transaction is expected to add approximately $3B of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per share by approximately $0.20.
Exact Sciences Shareholders Approve Abbott Acquisition
Exact Sciences (EXAS) announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (ABT) at the special meeting of stockholders. Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026.
Exact Sciences Reports Q4 Revenue of $878M, Exceeding Expectations
Reports Q4 revenue $878M, consensus $860.76M. "In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests," said Kevin Conroy, Chairman and CEO of Exact Sciences. "These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients. As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally."
Exact Sciences Celebrates Federal Legislation for Medicare Coverage of MCED Tests
Exact Sciences celebrates the passage of federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection , or MCED, tests. "By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging technology for millions of Medicare beneficiaries," the company stated. "It's a historic day in the fight against cancer. We are deeply grateful to lawmakers, especially Representatives Terri Sewell and Jodey Arrington, patient advocates, and all those who fought tirelessly for this groundbreaking legislation. Most importantly, we are thrilled for the countless individuals whose lives will be impacted by these tests, potentially giving them more opportunities to celebrate birthdays, anniversaries, and precious moments with their loved ones," said Kevin Conroy, chairman and CEO of Exact Sciences.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。